Indication V

Therapy: FDA-approved, new, engineered small molecules targeting the Porosome secretory machinery to modulate and treat diseases resulting from secretory disorders.

Status: Preclinical. Five FDA-approved, new, engineered small molecules identified and undergoing in vitro and

in vivo studies. Mechanism of action of identified small molecules determined in silico.

Commercial Value: Our AI drug development platform with five identified, preclinical, or early-stage clinical drug assets hold significant, yet highly leveraged, commercial value. As of 2026, similar platforms have been valued in the hundreds of millions to low-billion-dollar range, driven by partnerships with "Big-Pharma," reduced preclinical costs (up to 40%–70% lower), and the potential to accelerate discovery timelines. The value is also driven by the ability to significantly compress early discovery timelines (often by 30-40%) and increase preclinical hit rates (up to 20x higher than traditional methods).